LIMN Liminatus Pharma, Inc.
$3.16▲ +7.48%
Healthcare
Other
Volume 9.4K
Avg Volume (10D) 31.4K
Key Metrics & Fundamentals
Market Cap
$4.24M
P/E Ratio
–
Div Yield
0.00%
52W Range
2.91 - 141.50
% vs 50 MA
-19.46%
% vs 200 MA
-73.21%
RSI-14
40.3
MACD Histogram
-0.0100
Beta (1Y vs SPY)
0.29
Free Cash Flow
-$969,999
Gross Rev
$0
Gross Profit
$0
EBITDA
-$1.37M
COGS
–
Operating Exp
$1.38M
Operating Income
-$1.38M
EBIT
-$1.38M
Pretax Income
-$1.41M
Net Income
-$1.41M
EPS (Diluted)
-0.03
Price & Volume History
Loading chart…
Recent News
Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
GlobeNewswire · Sep 29, 2026 9:00 AM ET
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
GlobeNewswire · Aug 24, 2026 8:00 AM ET
Liminatus Pharma Reports Reverse Stock Split
MT Newswires · Aug 18, 2026 4:51 PM ET
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
GlobeNewswire · Aug 18, 2026 4:01 PM ET
BC-Most Active Stocks
Associated Press · Aug 13, 2026 10:30 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See LIMN's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.